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Giant-Cell Tumor of the Tendon Sheath in the
Upper Cervical Spine
Introduction
Giant-cell tumor of the tendon sheath (GCTTS) is part of the
group of synovial tumors that can affect joints, bursas, and tendon
sheaths.1,2 It is rare forGCTTS to involve the spine.Whenpresent, it is
more common in the lower cervical spine. In the literature, there are
only four cases described in the upper cervical spine.2-5 In this report,
we describe a rare case of GCTTS in the upper cervical spine, which
was treated with en-bloc marginal resection.
Case Report
A 31-year-old patient, previously asymptomatic, underwent
computed tomography (CT) of the cranium for investigation of a
complicated otitis media. The imaging examination revealed a tumor
of the upper cervical spine. The lesion was located in the region of the
intervertebral foramina between C1 and C2, on the right side, with a
mass of soft tissue in the epidural and foraminal regions involving the
root of C2. There were no signs of bone destruction on cervical
angiotomographyof the spine,which revealedproximity to the tumor
and vertebral artery (Fig 1; [A] computed angiotomography with
paramedian right sagittal reconstruction showing the lesion and the
vertebral artery; [B andC] axial slices demonstrating the involvement
of the C1-C2 foramen and the relationship with the right vertebral
artery). Tomographies of the chest, abdomen, and pelvis; bone scin-
tigraphy with technetium; and cervical spinemagnetic resonance im-
aging (MRI) examinations were performed, and no other neoplastic
lesions were found (Fig 2; axial cervical spine MRI with gadolinium
showing [A] lesion at C1-C2, involving right C2 nerve root, and [B]
lesion around the lamina of C2).
The patient underwent a percutaneous biopsy guided by CT.
Little material could be obtained, and the anatomopathologic result,
although inconclusive, was suggestive of malignant neoplasm.
Three months after identification of the neoplasia, the patient
began to experience intense, progressive pain in the upper cervical
region,withrightoccipital andhemicranialpain.Becauseof the lackof
a conclusive anatomopathologic result and the presence of symptoms
related to tumor growth, surgical treatment was indicated, aimed at
en-bloc resection of the tumor.
The surgical procedure was performed through a posterior ap-
proach to theupper cervical spine.Afibroelasticmasswas identified in
the foraminal region betweenC1 andC2, involving the laminae of C1
and C2, without evident signs of bone involvement at surgery (Fig 3;
operative viewof the lesion, between theC1archand theC2 lamina, at
right). A right hemilaminectomy of C1 and C2 was performed to
remove the tumor. The root of C2, on the right, was ligated, and the
tumor was resected en bloc. At the end of the procedure, an
accidental lesion of the right vertebral artery was identified. The
artery was ligated, without any functional complications in the
postoperative period.
The anatomopathologic examination showed a tumor weighing
5 g, with a volume of 2.2 2.0 1.5 cm andmarginal margins. The
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result of the immunohistochemical examination (Table 1) was com-
patible with localizedGCTTS (Fig 4; nodular fragment of tissue,mea-
suring 2.2 2.0 1.5 cm after ressection).
Thepatient continuedwithout postoperative complications, and
the headaches disappeared. After 18 months of follow-up, she
presented with mild, intermittent cervical pain and a reduction of
approximately 30% in the cervical rotation range of movement. The
controlMRI at that time showed no signs of tumor recurrence (Fig 5;
control magnetic resonance imaging, showing no signs of tumor recur-
rence;white arrow indicates absence of flux in right vertebral artery).
Discussion
GCTTS is also known as pigmented villonodular synovitis. It can
be divided into two forms: localized and diffuse. The diffuse form is
generally found in the large joints, like the knee or hip. The localized
form is more common, and it more often occurs in the hands, feet,
and knees.1
Approximately 50 cases of GCTTS of the spine are described in
the literature. Approximately half of all cases occur in the lower cervi-
cal region, followed by the lumbar and thoracic spine.3,6,7 The upper
cervical region isa rare site for theoccurrenceofGCTTS,andonly four
cases have been described to date.2-5
Because of its rarity, GCTTS of the axial skeleton is often not
included in the differential diagnoses for lesions of the upper cervical
spine.There is often anextensionof the tumor into the epidural space;
therefore, the differential diagnosis in imaging examinations includes
benign diseases, such as schwannomas andmeningiomas, andmalig-
nant diseases, like metastases.8-10
The pathogenic mechanisms of GCTTS are still unknown. They
are characterized by a proliferation of mononuclear, often circum-
scribed, cells. There are also variable numbers ofmultinucleated oste-
oclast and inflammatory cells, with fibrous, hyalinized stroma.
Cytogenetic studies show numeric and clonal chromosome changes,
suggesting a neoplastic cytogenetic mechanism.11,12 GCTTS express
high levels of colony-stimulating factor 1 receptor (CSF1R).12West et
al12 determined that the CSF1 gene, which encodes the ligand of
CSF1R, is translocated in only 2% to 16% of tumor cells, suggesting
that only few GCTTS cells are neoplastic. Most cells in the tumor
BA
Fig 2.
Fig 3.
Table 1. Immunohistochemistry Results
Antigen Result
KI-67 Positive (low index)
EMA Negative
Vimentine Positive
CD68 Positive
CD34 Negative
Protein S100 Negative
Desmine Negative
Abbreviation: EMA, epithelial membrane antigen.
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would be reactive and recruited by the increased production of CSF1
by the neoplastic cells.12
Immunohistochemical and electronic microscopic findings
show that proliferating cells have characteristics of synovial cells and
fibroblasts as well as hystiocytes. Recently, the immunohistochemical
marker clusterin,which isnormally expressed innormal synoviocytes,
was also shown to be positive inGCTTS, in both diffuse and localized
forms.13 This characteristic demonstrates that neoplastic cells have
synovial differentiation.
The high cellularity of this lesion, along with the presence of
frequent mitoses, can lead to incorrect interpretation of a sarcoma.
The differential diagnosis in the pathologic anatomy includes epithe-
lioid sarcoma and malignant fibrous hystiocytoma, which present
necrosis and anaplasia. Pigmented villonodular synovitis located in
the joint is histologically similar.13 However, it has papillary projec-
tions and pseudoglandular spaces covered by synovial cells as well
as hemosiderin.
It was once thought thatGCTTSwasmore common inwomen,3
but in fact, it is equally distributed between sexes.3,6 It can occur in
from age 7 to 81 years; there have been a high number of patient cases
between the third and fifth decades of life.3,6,14
In the vertebral column, the most common description of the
originof the tumor is the synovialmembraneof the facet joints,3 but it
can also originate in bursas.2 It is not always possible to correctly
identify the origin of the lesion. In our patient, the lesion probably
originated in the facet joint between C1 and C2, and tumor growth
was predominantly extra-articular.
GCTTS of the spine can be asymptomatic or may be associated
with axial pain, radicular pain, or neurologic deficit, dependingon the
sizeand locationof the tumor.3 In thecasedescribedhere, thepatient’s
symptoms were related to compression of the C2 nerve root on the
right side.
In imaging examinations, GCTTS may have a variable appear-
ance. In a CT scan, the lesion may demonstrate hyperattenuation
resulting fromhemosiderincontent.7Thematrixof the tumor is rarely
calcified.10 Sometimes, it occurs as a tumor in the soft tissue and, other
times, as a destructive bone lesionwith pressure erosion, and sclerotic
margins of the posterior elements of the vertebra, associated with a
nodular soft tissuemass.10 Inourpatient, the lesion caused awidening
of the foraminal space between C1 and C2with bone remodeling as a
result of the growth of soft tissue mass.
In anMRI, the lesion is isointense to the muscle in T1-weighted
images. Areas of low or intermediary signal can be found because of
the presence of hemosiderin, which is accentuated in echo gradient
sequences in T2-weighted images.10,15 However, it can demonstrate
variable appearance depending on mass composition, which may
have variable content of hemosiderin, liquid, lipids, fibrous tissue, and
hemorrhage.10 The small number of described GCTTS cases occur-
ring in the spine, along with the variable character of theMRI, makes
differential diagnosis of the tumor difficult.10 In our patient, the
GCTTS diagnosis was not considered among the diagnostic possibil-
ities during evaluation of the imaging examinations.
The recommended treatment for GCTTS, because of its aggres-
sive nature, is complete resectionwhenever possible.16-18 In the spine,
the estimated rate of local recurrence is 18%,6 which is comparable to
that of GCTTS of the apendicular skeleton.19 Our patient has been
undergoing follow-up for 18 months, without any signs of local re-
lapse in imaging examinations after marginal en-bloc resection.
Recently, the use of imatinib was described for treating tenosy-
novial sheath giant-cell tumor inpatientswith recurrent or irresecable
lesions.20,21 Cassier et al22 performed an international multicentric
retrospective study to evaluate the use of imatinib in 16 patients with
GCTTS. One patient (6%) had a complete response, two (13%) had
partial responses, and in eight (50%), the disease stabilized. It seems
that the use of imatinib is promising for patients with recurrent and
inoperable lesions, although this should be confirmed by prospective
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clinical studies. The inhibitionof tumoral growthmaybemediatedby
imatinib activity against CSF1R.22,23
Despite the rarity of the disease, GCTTS should be considered
during differential diagnosis of lesions of the axial skeleton located
close to the intervertebral foramen. Knowledge of the existence of this
tumor is important, because the radiologic characteristics can simu-
late other neoplastic diseases of the spine.
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